Trethera is a biotechnology company that discovers and develops small molecules that control DNA replication and integrity.This approach is designed to overcome the limitations of single agent treatments and the associated risks of treatment failure and drug resistance. The combination therapy is addressing the alternative pathways of nucleotidebiosynthesis, namely the de novo and the salvage pathways, as well as the mechanisms that protect the cancer genome against DNA replication stress and damage. The combination therapy causes an imbalance in the supply and demand of nucleotides which is lethal to cancer cells and well-tolerated by normal tissues.
